Divine Aleru, Microbiome Medicine Research Coordinator

This review explains intestinal effect of Escherichia coli Nissle 1917 and its vesicles on the gut barrier, dysbiosis and mucosal immunity, and it links these microbial actions to clinical outcomes in inflammatory bowel disease and acute diarrhoea.

Oral delivery of a glypican-1–flagellin fusion by engineered EcN triggered systemic IgG and regulatory IL-10 in mice, confirming a safe probiotic cancer-vaccine chassis but indicating the need for stronger cellular adjuvanticity for PDAC.

Engineered Escherichia coli Nissle 1917 Pseudomonas aeruginosa control was tested as a live targeted therapy for gut infection. The authors rebuilt the earlier “sense-and-kill” circuit in a clinically used EcN background. The circuit sensed the P. aeruginosa quorum signal 3OC12-HSL. It then triggered lysis and release of pyocin S5, an antipseudomonal bacteriocin. […]

Engineered EcN for phenylketonuria was upgraded to SYNB1934 using biosensor-enabled PAL evolution, doubling gut phenylalanine conversion and keeping biocontainment, supporting development of an oral strain for diet-refractory PKU.

Engineered Escherichia coli Nissle 1917 for hyperammonemia (SYNB1020) safely consumed gut ammonia, improved survival in mice, and showed dose-linked metabolic activity and clearance in healthy adults, supporting clinical development for urea cycle and liver-related hyperammonemia.

Engineering Escherichia coli Nissle 1917 therapeutics enables targeted antimicrobial, mucosal, metabolic, and anticancer actions but requires parallel engineering for biosafety and colibactin control.

Escherichia coli Nissle 1917, a probiotic strain, offers significant health benefits, but its genotoxic potential due to colibactin production raises safety concerns, particularly in relation to colorectal cancer. The review underscores the need for further research on the balance between benefits and risks.

Escherichia coli Nissle 1917 reduces the incidence of acute respiratory infections in late preterm newborns during the first month of life, with no adverse effects, highlighting its potential as a prophylactic intervention in this vulnerable population.

This study demonstrates that engineered E. coli Nissle 1917 can selectively colonize colorectal adenomas and reduce tumor burden in mice. The probiotic also shows promise for non-invasive detection and treatment of CRC in humans, suggesting a novel therapeutic and diagnostic platform.

Escherichia coli Nissle 1917 (EcN) shows promise as a tumour-targeting probiotic bacterium for cancer treatment and detection. This review investigates its tumour-homing abilities and outlines future research directions to optimize its use in clinical oncology.

This review analyzes the advancements in preventing urinary catheter-related infections (CAUTIs) through scientific publications and patents, highlighting innovations like antimicrobial-coated catheters and biofilm-resistant materials, with implications for clinical practice and healthcare systems.

Probiotic Escherichia coli Nissle 1917 iron competition reduced Salmonella in inflamed murine gut by using lipocalin-2–resistant siderophores and by dampening mucosal inflammation, showing a nutritional immunity route for probiotic therapy.

Escherichia coli Nissle 1917 acute diarrhoea therapy in infants and toddlers shortened illness from 4.8 to 2.5 days, raised response to 94.5%, and was as safe as placebo.

Escherichia coli Nissle 1917 improved IBS modestly overall but clearly in postinfectious or postantibiotic IBS, was as safe as placebo, and fits a dysbiosis-linked microbiome signature that needs 10–12 weeks of therapy to show.

Escherichia coli Nissle 1917 (EcN) significantly enhances protection against human rotavirus in gnotobiotic pigs by modulating plasmacytoid dendritic cells and NK cell responses, suggesting its potential as an effective probiotic treatment for viral gastroenteritis.

Escherichia coli Nissle 1917 (EcN) is a safe and effective probiotic for maintaining remission in ulcerative colitis patients, with clinical trial evidence showing equivalence to mesalazine in relapse prevention. Its mechanisms include immune modulation, antimicrobial activity, and gut barrier reinforcement.

Escherichia coli Nissle 1917 (EcN) interferes with the invasion of human intestinal epithelial cells by various pathogens through a secreted component, not by microcins or physical contact, suggesting its potential as a therapeutic probiotic to prevent gastrointestinal infections.

This study uncovers the dual role of Escherichia coli Nissle 1917, where its beneficial antibacterial activity is linked to the ClbP protein, while its genotoxic effects are dependent on colibactin. Engineering strains that decouple these activities could lead to safer probiotic therapies.

The study explores how Escherichia coli Nissle 1917’s microcins mediate competition in the inflamed gut, showing potential for therapeutic use in enterobacterial infections and colitis management.

E. coli Nissle uses yersiniabactin to bind zinc, overcome calprotectin, and colonize the inflamed gut, defining a metal-driven microbiome signature linked to Enterobacteriaceae dominance in colitis, with clear dependence on inflammation and pH.

Probiotic-e-coli-nissle-1917 shows benefit in ulcerative colitis, infant diarrhea, and innate immune priming, with transient engraftment and microcin-based pathogen suppression, but no effect in Crohn’s disease. Safety is strong, though neonatal products require caution.

E. coli Nissle 1917 is a non-pathogenic probiotic strain that inhibits pathogenic bacteria, reduces inflammation, and strengthens intestinal barrier function, with proven clinical efficacy in treating gastrointestinal diseases.

This study evaluates the inhibitory effects of Escherichia coli Nissle 1917 (EcN) on Clostridium perfringens type A, focusing on growth inhibition, toxin production, biofilm formation, and inflammatory cytokine responses in vitro.

Escherichia coli Nissle 1917 (EcN), a probiotic with a rich history, is now being engineered for therapeutic uses beyond gastrointestinal health, including metabolic disease treatment and immune modulation. Its potential in microbiome research and live vaccine development is also being explored.